CoChat

Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer

Zer, Alona, Sung, Mike R., Walia, Preet, Khoja, Leila, Maganti, Manjula, Labbe, Catherine, Shepherd, Frances A., Bradbury, Penelope A., Feld, Ronald, Liu, Geoffrey, Iazzi, Melissa, Zawisza, Dianne, Nouriany, Nazanin, Leighl, Natasha B. · 2018 · Clinical Lung Cancer
Cited by 134

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Micro‐Abstract: Programmed death‐1 (PD‐1) axis inhibitors have become standard therapy in advanced Non–Small‐Cell Lung Cancer (NSCLC). The relationship between clinical outcomes and neutrophil to lymphocyte ratio (NLR) and absolute neutrophil count (ANC) was explored in 88 advanced NSCLC patients treated with PD‐1 axis inhibitors. Patients with baseline NLR ≤4 had superior disease control rate, treatment duration, and survival. Lower NLR and ANC during treatment were associated with response and treatment duration. Introduction: Programmed death‐1 (PD‐1) axis inhibitors have become standard therapy in advanced non–small‐cell lung cancer (NSCLC). Response might be delayed and pseudo‐progression occasionally occurs in patients who eventually benefit from treatment. Additional markers beyond programmed death ligand 1 (PD‐L1) expression are needed to assist in patient selection, response evaluation, and treatment decisions. Materials and Methods: The relationship between prospectively collected clinical outcomes (response, disease control rate [DCR], treatment duration, overall survival) and hematologic parameters (neutrophil to lymphocyte ratio [NLR], absolute neutrophil count [ANC], and platelet to lymphocyte ratio [PLR]) was explored retrospectively in advanced NSCLC patients treated with PD‐1 axis inhibitors at a major cancer center from May 2013 to August 2016. Hematologic parameters at baseline and during treatment (week 2 or 3 and week 8) were included. Results: Of 88 patients treated with PD‐1 axis inhibitors, 22 (25%) experienced partial response. Baseline NLR ≤4 was associated with superior DCR (74% vs. 50%; P = .025), treatment duration (P = .037), time to progression (P = .053), and overall survival (P = .019), with no differential association according to PD‐L1 tumor expression. Lower NLR and ANC during treatment were also associated with response to treatment (P = .025 and P = .017, respectively), and treatment duration (P = .036 and P = .008). No association was found between baseline PLR and DCR, response, treatment duration, nor overall survival. Conclusion: Baseline NLR ≤4 and lower NLR and ANC during treatment might correlate with disease control and treatment response and should be explored further as potential predictors of treatment benefit in larger studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2018.04.008

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Zer, A., Sung, M. R., Walia, P., Khoja, L., Maganti, M., Labbe, C., Shepherd, F. A., Bradbury, P. A., Feld, R., Liu, G., Iazzi, M., Zawisza, D., Nouriany, N., & Leighl, N. B.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2018-09
Volume
19
Issue
5
Pages
426-434.e1
ISSN
1525-7304 (ISSN-L)
OpenAlex
W2802496191
Cited by
134
References
13
FWCI
5.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.